MRNA — Moderna Cashflow Statement
0.000.00%
Last trade - 00:00- $38.83bn
- $30.80bn
- $6.85bn
- 73
- 21
- 78
- 59
Annual cashflow statement for Moderna, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -514 | -747 | 12,202 | 8,362 | -4,714 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 77.7 | 166 | 196 | 285 | 286 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -53.7 | 2,577 | 1,308 | -3,455 | -139 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -459 | 2,027 | 13,620 | 4,981 | -3,118 |
| Capital Expenditures | -31.6 | -67.4 | -284 | -400 | -707 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 16.6 | -1,604 | -8,239 | -4,776 | 4,913 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -14.9 | -1,672 | -8,523 | -5,176 | 4,206 |
| Financing Cash Flow Items | 0.971 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 51.1 | 2,033 | -873 | -3,448 | -1,377 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -423 | 2,388 | 4,224 | -3,643 | -289 |